We may use the heart as a window to the brain
In the quiet machinery of the failing heart, researchers at the Medical University of South Carolina have found an unexpected mirror of the mind's own unraveling. Federica del Monte and her team have traced idiopathic dilated cardiomyopathy — a disease that hides until crisis — to the same protein misfolding signatures seen in Alzheimer's disease, revealing that a corrupted repair system turns the heart's own defenses against it. The discovery, a decade in the making, suggests that the heart may offer a diagnostic window into neurological disease before the brain itself shows signs of distress, inviting cardiology and neurology into a shared conversation they have rarely had before.
- A disease that can silently enlarge and weaken the heart for years is now linked to the same molecular chaos that destroys memory — raising the stakes for both conditions at once.
- The heart's protein repair system, rather than simply failing, is being chemically redirected toward cell death — a sabotage from within that worsens with age and Alzheimer's-linked genes.
- Patients with cardiomyopathy may be carrying early signs of Alzheimer's disease in their chests long before any neurological symptom surfaces, compressing the window for intervention.
- Del Monte is already pushing for heart ultrasounds in Alzheimer's clinics and neurological screening in cardiology wards, dissolving the boundary between two medical specialties.
- The search for biomarkers that could catch the disease before severe damage sets in is now underway, with parallel work in cancer research suggesting treatments may not be far behind.
A decade ago, Federica del Monte noticed something that didn't belong: in the hearts of patients with idiopathic dilated cardiomyopathy, a progressive and often silent weakening of the heart muscle, she found clusters of misfolded proteins that looked strikingly like the plaques of Alzheimer's disease. That observation became the seed of a decade-long investigation, now published in the Journal of Molecular and Cellular Cardiology, that has reshaped how two seemingly unrelated diseases are understood.
The research pinpoints the mechanism behind those mysterious plaques: a breakdown in the system that repairs damaged proteins in heart cells. Crucially, the failure lies not just in the repair machinery itself but in the chemical modifications — post-translational tags — that govern how it operates. In diseased hearts, those tags are abnormal, flipping the system from repair to cell death. The effect is more pronounced in older patients and in those carrying an Alzheimer's-linked gene, suggesting the heart's own defenses are being turned against it.
What makes the finding clinically urgent is its diagnostic implication. The characteristics of cardiomyopathy can appear in the heart before Alzheimer's symptoms emerge in the brain, offering a potential early warning window. Del Monte has begun advocating for cardiac ultrasounds in Alzheimer's clinics, and for neurological screening among heart patients. "We may use the heart as a window to the brain," she said.
The work was built across continents and careers — postdoctoral fellows who contributed years ago now hold faculty positions from Boston to Zurich to Italy. Co-first author Camilla Bacchin is now focused on identifying biomarkers that could catch the disease before serious damage occurs. The approach is already being explored in cancer research, and the convergence of cardiology and neurology it demands may soon yield shared treatments for patients who have long carried these conditions in silence.
A decade ago, Federica del Monte was working on something entirely different when she noticed something that shouldn't have been there. In the hearts of patients with a mysterious condition called idiopathic dilated cardiomyopathy—a progressive weakening of the heart muscle that often goes undetected until patients are in crisis—she found clusters of misfolded proteins. They looked exactly like the plaques that accumulate in Alzheimer's disease. The resemblance was too striking to ignore.
That observation set del Monte and her team at the Medical University of South Carolina on a path that has now reshaped how we think about two seemingly unrelated diseases. In research published this month in the Journal of Molecular and Cellular Cardiology and selected for the journal's cover, her lab has identified the precise mechanism behind those mysterious plaques: a breakdown in the system that normally repairs damaged or misfolded proteins in heart cells. The defect lies not just in the repair machinery itself, but in the chemical modifications that control how that machinery works—alterations so fundamental that they flip the switch from repair to cell death.
Idiopathic dilated cardiomyopathy is a disease that hides. Patients can carry it for years without symptoms, their hearts slowly enlarging and weakening, until suddenly they find themselves in advanced heart failure. There is no known cause, no clear trigger. The condition affects thousands of people, and for many, the first sign is catastrophic. Del Monte's discovery that the same protein plaques found in Alzheimer's brains also appear in these failing hearts suggested a deeper connection—one that might explain why the disease progresses the way it does.
The team examined the three major branches of the protein repair system, looking not just at the proteins themselves but at the post-translational modifications—chemical tags that activate or deactivate proteins. What they found was striking: in diseased hearts, these modifications were abnormal, and they were pushing cells toward death rather than repair. The modifications were worse in older patients and in those carrying an Alzheimer's-linked gene. In essence, the heart's own defense system was turned against it.
What makes this discovery particularly powerful is what it suggests about diagnosis and treatment. Del Monte has begun advocating for heart ultrasounds in Alzheimer's clinics, looking for the telltale signs of an enlarged, weakened left ventricle. The reverse is also true: cardiologists might screen for early signs of neurological disease in heart patients. "We may use the heart as a window to the brain," del Monte said. The characteristics of cardiomyopathy can appear in the heart before Alzheimer's symptoms show up in the brain—a window for earlier intervention.
The research represents a collaboration that stretched across a decade and multiple continents. Postdoctoral fellows who worked on the project years ago have since become faculty members at institutions from Boston to Zurich to Italy. Their contributions, del Monte emphasized, don't disappear when they move on. The work required that kind of persistence, that willingness to follow a thread across disciplines and years.
Camilla Bacchin, a postdoctoral fellow in the lab and co-first author of the paper, is now focused on the next step: finding biomarkers—molecular signatures that could identify the disease earlier, before the heart is severely damaged. The goal is straightforward but ambitious: diagnose earlier, treat earlier, prevent the disease from worsening. Del Monte noted that understanding the entire repair system, including these chemical modifications, is essential. "It needs to be checked in its entirety," she said. The approach is already being tested in cancer research, suggesting that treatments might not be far behind.
As the overlap between Alzheimer's disease and heart failure becomes clearer, cardiologists and neurologists are beginning to work together in ways they rarely have before. The window between heart and brain is opening wider, and with it comes the possibility of shared diagnosis, shared treatment, and earlier intervention for diseases that have long seemed separate. For patients who have carried these conditions silently, that convergence could mean the difference between detection and crisis.
Notable Quotes
The goal is to diagnose earlier and treat earlier to prevent the worsening of the disease.— Camilla Bacchin, postdoctoral fellow in the del Monte Lab
It needs to be checked in its entirety—understanding the entire repair system, including chemical modifications, is essential for moving forward.— Federica del Monte, senior researcher
The Hearth Conversation Another angle on the story
Why would a heart disease and a brain disease share the same protein plaques? That seems almost impossible.
It does seem unlikely until you realize both are fundamentally protein misfolding diseases. The plaques aren't unique to the brain—they're a symptom of a system that's broken down. The heart and brain both rely on the same repair machinery, and when that machinery fails in the same way, you get the same result.
So the heart is showing us what's happening in the brain before we can see it there?
Exactly. The heart changes appear first, sometimes years before any neurological symptoms. That's the real insight—we've been looking at two separate diseases when we should have been looking at one problem manifesting in two places.
What does it mean that these chemical modifications are pushing cells toward death instead of repair?
It means the cell is getting a signal to self-destruct when it should be getting a signal to fix itself. The modification is there, the protein is there, but the instruction is backwards. Age and certain genes make it worse.
If you can find these changes early, what happens next?
That's where biomarkers come in. If we can identify the molecular signature of the disease before the heart is severely damaged, we can treat it. We're already seeing similar approaches work in cancer. The question is whether we can move from understanding the mechanism to actually preventing the disease.